HomeSearch the SiteDoctor Finder

350 Engle Street, Englewood NJ 07631 * Tel.: 201-894-3636 *

Bloodless News



Englewood Hospital and Medical Center Begins Clinical Trials for Blood Substitute

Anesthesiologists at Englewood Hospital and Medical Center have begun clinical trials of OxygentTM, a 'blood substitute', in cooperation with Alliance Pharmaceutical Corp. The dose escalation study is being conducted with non-cardiac patients with high anticipated blood loss. Patients participating in the study so far, underwent operations to treat abdominal aortic aneurysms. 'We are looking to see what levels of the drug can be well tolerated by our patients,' said Aryeh Shander, MD, Chief of the Department of Anesthesiology and Critical Care Medicine. 'This Oxygen carrying substance is interesting to physicians because it could reduce a patient's exposure to donor blood. These 'blood substitutes' also have the potential of reducing the demand for donor blood.' Dr. Shander explained further that there is growing evidence indicating that blood transfusions should be avoided because exposure to donor blood compromises the immune system increasing the risks of recurrence of cancer and the development of post- operative infection. These effects could be substantially reduced.

Sherri Ozawa, RN, Director of Englewood Hospital and Medical Center's New Jersey Institute For The Advance-ment of Bloodless Medicine and Surgery with Feng Qin, MD in the OR assisting in the clinical trial of OxygentTM.

An intravascular oxygen carrier (temporary 'blood substitute'), OxygentTM is administered according to Alliance's proprietary Augmented Acute Normovolemic Hemodilution procedure. The Oxygen carrying substance behaves in the same way as red blood cells -- picking up Oxygen and dropping it in the tissues, and picking up Carbon Dioxide for removal. OxygentTM is compatible with all blood types, has a shelf-life of about two years, and is produced in commercial scale quantities using a cost-effective manufacturing process. According to Alliance's projection of the substance's potential market, 'approximately 4 million surgical procedures are performed annually in the U.S. and 8-10 million worldwide, wherein two to four units of donor blood are anticipated to be used.'

Englewood Hospital and Medical Center's New Jersey Institute For The Advancement of Bloodless Medicine and Surgery is the largest dedicated program for transfusion-free medicine in the world and a clinical site for numerous studies.

For more information call Dr. Shander at (201) 894-3238.